Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Status:
Suspended
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
To assess the usefulness of Gemcitabine plus S-1 therapy based on the antitumor effect and
survival period. By performing a phase I/II study of this combination in patients with
inoperable or with postoperative pancreatic cancer.